News

Details

Published: 27 July 2020

• portfolio-news

CARISMA Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the Company's lead product candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). Under this IND, CARISMA intends to initiate its Phase 1, first-in-human, multi-center study in patients with recurrent or metastatic HER2 overexpressing solid tumors after failure of approved HER2 targeted agents. 

Details

Published: 22 July 2020

• portfolio-news

Quanta today announced the appointment of Hooman Hakami to the Company’s Board as an independent Non-Executive Director, with immediate effect. Hooman has 30 years of leadership experience, including senior positions at two of the world’s largest medical devices companies. At Medtronic, he was Executive Vice President and President of the Diabetes Group and prior to that he spent more than 20 years at General Electric, where he was a Company Officer. 

Details

Published: 02 July 2020

• portfolio-news

Immatics (NASDAQ: IMTX) today announced the completion of its business combination with Arya Sciences Acquisition Corp. (NASDAQ: ARYA), a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. Today, Immatics will commence trading its shares under the symbol “IMTX” and its warrants under the symbol “IMTXW” on the Nasdaq Capital Market. Proceeds from this transaction were approximately $253 million, which included funds held in Arya’s trust account and the common stock private investment in public equity (PIPE) financing contributed by a group of leading US healthcare institutional investors.